Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Semin Cancer Biol. 2021 Nov 26;82:68–93. doi: 10.1016/j.semcancer.2021.11.001

Fig. 10. AR−/lo CRPC is insensitive to Enza and BCL-2 is upregulated by castration.

Fig. 10.

A. Schema in generating paired xenograft AD tumors, primary CRPC (ADT-resistant) and secondary CRPC (both ADT/Enza-resistant) in LNCaP, VCaP, LAPC4 and LAPC9 models.

B. The above 4 xenografts develop unique AR expression patterns as they evolve towards CRPC. P, passage (of tumors in mice).

C. BCL-2 was elevated in 3 of the 4 CRPC xenograft (except VCaP) models.

D. BCL-2 was further increased in the LNCaP secondary CRPC model.

E. Distinct responses of the 4 xenograft CRPC models to Enza (see Text). Green arrows indicate the time when treatment of tumor-bearing mice was started.

All panels in the Figure were adapted with permission from reference [163].